Unknown

Dataset Information

0

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?


ABSTRACT: Contrary to the approved indication for pegfilgrastim prophylaxis, some patients receive it on the same day as the last administration of chemotherapy in clinical practice, which could adversely impact risk of febrile neutropenia (FN). An evaluation of the timing of pegfilgrastim prophylaxis and FN risk was undertaken.A retrospective cohort design and data from two US private health care claims repositories were employed. Study population comprised adults who received intermediate/high-risk chemotherapy regimens for solid tumors or non-Hodgkin's lymphoma (NHL) and received pegfilgrastim prophylaxis in ?1 cycle; all cycles with pegfilgrastim were pooled for analyses. Odds ratios (OR) for FN during the cycle were estimated for patients who received pegfilgrastim on the same day (day 1) as the last administration of chemotherapy versus days 2-4 from chemotherapy completion.The study population included 45,592 patients who received pegfilgrastim in 179,152 cycles (n?=?37,095 in cycle 1); in 12 % of cycles, patients received pegfilgrastim on the same day as chemotherapy. Odds of FN were higher for patients receiving pegfilgrastim prophylaxis on the same day as chemotherapy versus days 2-4 from chemotherapy in cycle 1 (OR?=?1.6, 95 % CI?=?1.3-1.9, p?

SUBMITTER: Weycker D 

PROVIDER: S-EPMC4805705 | biostudies-other | 2016 May

REPOSITORIES: biostudies-other

altmetric image

Publications

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?

Weycker Derek D   Li Xiaoyan X   Figueredo Jacqueline J   Barron Rich R   Tzivelekis Spiros S   Hagiwara May M  

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20151125 5


<h4>Purpose</h4>Contrary to the approved indication for pegfilgrastim prophylaxis, some patients receive it on the same day as the last administration of chemotherapy in clinical practice, which could adversely impact risk of febrile neutropenia (FN). An evaluation of the timing of pegfilgrastim prophylaxis and FN risk was undertaken.<h4>Methods</h4>A retrospective cohort design and data from two US private health care claims repositories were employed. Study population comprised adults who rece  ...[more]

Similar Datasets

| S-EPMC6199230 | biostudies-literature
| S-EPMC7892737 | biostudies-literature
| S-EPMC4846701 | biostudies-literature
| S-EPMC6716357 | biostudies-literature
| S-EPMC5091320 | biostudies-literature
| S-EPMC6089155 | biostudies-literature
| S-EPMC2752227 | biostudies-other
| S-EPMC9179461 | biostudies-literature
| S-EPMC7283414 | biostudies-literature
| S-EPMC3994907 | biostudies-literature